KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Issued (2020 - 2025)

Aurinia Pharmaceuticals' Shares Issued history spans 6 years, with the latest figure at $13.8 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 736.2% year-over-year to $13.8 million; the TTM value through Dec 2025 reached $14.2 million, up 73.34%, while the annual FY2025 figure was $14.2 million, 73.34% up from the prior year.
  • Shares Issued reached $13.8 million in Q4 2025 per AUPH's latest filing, up from -$10.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $24.3 million in Q4 2021 to a low of -$10.2 million in Q3 2025.
  • Average Shares Issued over 5 years is $2.6 million, with a median of $1.3 million recorded in 2025.
  • Peak YoY movement for Shares Issued: soared 249850.0% in 2021, then plummeted 1029.89% in 2023.
  • A 5-year view of Shares Issued shows it stood at $24.3 million in 2021, then crashed by 100.76% to -$184000.0 in 2022, then tumbled by 1029.89% to -$2.1 million in 2023, then surged by 179.32% to $1.6 million in 2024, then soared by 736.2% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Shares Issued are $13.8 million (Q4 2025), -$10.2 million (Q3 2025), and $1.3 million (Q2 2025).